At 3 months post-baseline a third infliximab infusion was offered in those 3 patients who had the least improvement of DME. Repeated OCT after 2 months revealed a further decrease of macular thickness in 3 of 5 eyes, by 7 %, 15 % and 23 %, respectively. At this point the patient who still had the most severe condition received a fourth infliximab infusion; remarkably, a repeated OCT two months later revealed a marked resolution of severe DME, while BCVA had improved from counting fingers at baseline to 0.2. Infliximab therapy was well tolerated and no ocular or extra-ocular side effects were noted. In further available follow-up ranging from 4 to 7 months post-treatment, a recurrence of DME was observed in 2 of 5 eyes, albeit at a less severe level.